focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Old news, but you are correct.
"Users can input their test results into the Saturn Pass App, a digital health passport, for work, travel and leisure purposes. The intuitive app validates test results via facial recognition and identity documentation, providing a unique time-limited QR code to confirm a user’s results."
"The app asks users to scan a QR code on the RSPT to begin the process, ensuring only valid tests are used. A binding e-signature on a legal declaration cements integrity.
The app prompts users to record a video taking the test, requiring a photo of the result to validate results. Computer Vision AI is applied to support identity verification. Once the audit is fully verified, a limited life unique QR ‘COVID Pass’ is issued to the user.
This can then be presented to verify the user’s results for work, travel and leisure purposes."
infor25,
I replied to Sir Al thanking him for his response (it was quite lengthy and I was surprised he had taken so much time over it.)
I mentioned that there had been some general confusion over the term 'most infectious' and suggested this could be a good topic to cover whenever he's next being interviewed.
I agree AfamaMan. I think it's likely that we'll see this information corrected now Sir Al is aware. I hope that when the new website goes live it's very clearly marketed as an antibody test.
PART 2:
I sent an email to Avacta last night expressing my concerns at Medusa’s sales literature. To my surprise I received an email back from Sir Al himself just after 8am this morning. I’m not going to copy and paste his email onto a public BB as I don’t believe that’s a fair thing to do. Here’s a summary in MY OWN WORDS but without any of the stated information altered.
____
There are many IgM//Igm tests already on the market and these antibodies don’t appear until at least a week into the infection. In a sense, it’s true that an antibody test can detect current infection but what everybody wants is a test which can identify the infectious people.
The infectious time period is around 2 days before symptoms appear, up to approximately 7 days at which point the viral load begins to fall. Therefore, by the time antibodies are made you’re mostly through the infectious/most infectious time period.
Governments are wanting to move towards widespread weekly testing to find the people who are most infectious (remember these words from the recent RNS, I know some people picked up on it and took it as a negative). This is what Governments are asking for and this is what a lateral flow antigen test can do, unlike centralised testing such as PCR.
___
It was a really great response from Sir Al. He did not pass comment as to whether he thought Medusa’s advertising was misleading, but nor would I expect him to. My hope is that he will contact them and when the website is updated (apparently that will be this week), it won’t include claims that their anti-body test can detect current infection as that’s somewhat misleading.
With all the bad articles on Boohoo lately, if there was an outbreak in a workplace after testing with their products had been completed and returned negative because they were the wrong type of test… can you imagine the newspaper stories! It would not be good.
PART1:
Medusa are now taking pre-orders for their own branded antibody test. It's made by Agile Life Sciences and CE marked for professional use only with FDA approval pending.
I made some enquiries with them about placing an order for my business. I was told the minimum order was 50 units at £40+VAT each, delivery is expected within 4 weeks. I was also sent some photographs (the kit includes the LFA, two buffers, small pot and a pippet) and also a sales brochure.
To my concern, the sales brochure includes the following:
"The RSPT detects an immune response to the virus, indicating whether users have an active or recent infection, helping to guide decisions around the need to self-isolate, or the ability to travel and safely get back to work."
Whilst I didn’t believe it to be true, the claim of detecting active infection was a big worry. After some discussion with PL75 who did some research to confirm, I was confident it’s definitely an antibody test and this incorrect.
I raised a query with Medusa about the difference between the Avacta and Medusa tests and they simply told me that the Avacta test is aimed at consumers who can buy one at a time. Absolutely no other differentiation was given. Again, very worrying.
The new Medusa website is apparently going live later this week complete with online shop. If Medusa start advertising a lateral flow assay which can detect current infection it’s going to cause panic. To less knowledgeable investors, it could appear that we’ve been beaten to market… and by own our distributor!
Of course, we all know that Medusa are prohibited from selling a competing antigen test – but it could appear to some that a loophole had been found, or they were just doing it anyway. The last thing we want as investors is a panic sell off until clarification is given.
Welcome to Awacta.
Please don't be put off by all the recent childish bickering which happens on this board. There's a lot of very well informed people here who have been posting good info regularly for months.
Everybody keeps a close eye on whats happening with both Awacta and any potential competitors (not that there's any true competition yet anyway). Anything that happens, you'll normally find somebody has posted it on this board very quickly. Aside from the bickering, it's probably one of the most informative boards you'll come accross.
Good luck, hope we all do well!
Hold for gold indeed Tom!
The hardest lessons I've learnt have been from selling too soon. Many years ago I would do my research, buy, get impatient/nervous and sell. A few weeks later I would then realise I was right and completely missed out by selling too soon. I've been along for the ride here since April. At no point have I ever doubted Awacta's ability to deliver.
It's taken longer than I expected, but at no point has there been anything to indicate Awacta could fail.
Post of the day RR, well done.
I strongly believe we will have big news within the next 13 trading days. With new cases clearly creeping up in the UK and cold/flu season just around the corner... the timing couldn't be better from a sentiment perspective IMO...
A lot of people are definitely very worried about the problems which lie ahead going into the autumn and winter... Awacta offers a solution...
The way the ODX board are wetting themselves with excitement is tragic.
They don't understand that Mologics test is just being used for proof of concept and they're miles away from bringing it to market. Also, as per my previous post, Heathrow WILL NOT get to decide that a particular test is adequete for arrivals not to quarantine. Only the UK Government can make that decision.
AlwaysWhining is either the worlds worst deramper or a fake account made by somebody with a long position to put forward terrible arguements which are immediately destroyed, thus effectively ramping the share.
Depending on which is true, AlwaysWhining is either an idiot or a genius but I'm not sure which!
Either way, please do continue posting. It's great!
In relation to the LFD, I believe there's a high probability that by the time we receive the S&S data that BBI will have produced a good quantity of launch stock ready for market (whether that be for consumers or the UK gov) and this update will also be contained within the same RNS. I'm personally expecting this next week, if not the following.
Futher to the above, we are still expecting to hear of other manufacturing partners. I would imagine (and I don't know for sure) that any compnaies in the CONDOR program will be bound by a non-disclosure agreement. To my mind this makes sense, because any leaks to the media of upcoming tests could be problematic if the tests were to subsequently fail. There's been so many problems to date, I can't imagine our Gov want the media setting any expectations to the public until solid data is available. I've tried to find some evidence that there could/would be an NDA in place and I haven't been able to find any, so this is just my own guess as it seems logical.
Therefore, I think it's entirely possible we could receive a bumper RNS containing:
1. S&S
2. Confirmation that initial batches have been produced
3. Other manufacturing partners
In relation to BAMS, as per the June RNS:
"We are now looking forward to testing the prototype BAMS assay with patient samples in the UK very soon, whilst Adeptrix does the same at a site in the US. This will keep us on track for launch of a product for professional use in the summer."
Whilst I believe this is currently beyond Avacta's control and Sir Al is not to blame, as of tomorrow we go into overdue territory based upon most peoples interpretation of "summer."
If I were to hazard a guess, I'm expected BAMS news wk1/wk2 September, with LFD news wk2/wk3 September.
I also maintain my opinion of the past few months that the big news may not land at 7am.
All my opinion, could be way off the mark. Don't take as fact.
Guessing you haven't flown EasyJet lately.
Even with airlines which do have check in staff, they would need to observe the test being done. That's going to lead to some fairly long queues...
Always Whining
So you're suggesting that making a LFD with saliva as the sample is just as easy as making a PCR test? As there's no competition, I think we can safely assume it's fairly difficult...
What type of simpler and cheaper test do you have in mind? Specifically. Lets hear it.